bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary methods from Primary Preclinical and Clinical Evaluation of 68Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Authors: Li Fei , Zhang Zhenzhong , Cai Jiong , Chen Xi , Zhou Ying , Ma Xiangyi , Dong Qingjian , Li Fang , Xi Ling
Published: April 2023

Supplementary methods
Supplementary Data from The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response
Authors: Law Henry C.-H. , Lagundžin Dragana , Clement Emalie J. , Qiao Fangfang , Wagner Zachary S. , Krieger Kimiko L. , Costanzo-Garvey Diane , Caffrey Thomas C. , Grem Jean L. , DiMaio Dominick J. , Grandgenett Paul M. , Cook Leah M. , Fisher Kurt W. , Yu Fang , Hollingsworth Michael A. , Woods Nicholas T.
Published: April 2023

Text file containing supplementary information.
Supplementary Figure Legend from Primary Preclinical and Clinical Evaluation of 68Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Authors: Li Fei , Zhang Zhenzhong , Cai Jiong , Chen Xi , Zhou Ying , Ma Xiangyi , Dong Qingjian , Li Fang , Xi Ling
Published: April 2023

Supplementary Figure Legend
Figures S11-S16 from The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response
Authors: Law Henry C.-H. , Lagundžin Dragana , Clement Emalie J. , Qiao Fangfang , Wagner Zachary S. , Krieger Kimiko L. , Costanzo-Garvey Diane , Caffrey Thomas C. , Grem Jean L. , DiMaio Dominick J. , Grandgenett Paul M. , Cook Leah M. , Fisher Kurt W. , Yu Fang , Hollingsworth Michael A. , Woods Nicholas T.
Published: April 2023

Figure S11: The three-dimensional score plot of the PLS-DA proteomic subtype prediction model, and the receiver operator curves for the signature scores of the metabolic, progenitor-like, proliferative and inflammatory, respectively. Figure S12: The Kaplan-Meier curves corresponding to the pro-survival proteins in the proteome. Figure S13: The Kaplan-Meier curves corresponding to the anti-survival proteins in the proteome. Figure S14: The Kaplan-Meier survival curves for TYMP, PDCD6IP, STMN1, and ERAP1 proteins. Figure S15: Identification and validation of SHMT1 in gemcitabine resistance in PDAC cell lines. Figure S16: The gating strategies of the cell cycle analysis for the shSHMT1 MIA PaCa-2 cells.
Supplementary Fig S1 from Primary Preclinical and Clinical Evaluation of 68Ga-DOTA-TMVP1 as a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer
Authors: Li Fei , Zhang Zhenzhong , Cai Jiong , Chen Xi , Zhou Ying , Ma Xiangyi , Dong Qingjian , Li Fang , Xi Ling
Published: April 2023

The expression of VEGFR-3 detected by IF (A) and western blot (B) in LEC, LEC(shVEGFR-3) and HUVECs.
Supplementary Figure Legend from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma
Authors: Barry Wesley E. , Jackson Jeremy R. , Asuelime Grace E. , Wu Hong-Wei , Sun Jianping , Wan Zesheng , Malvar Jemily , Sheard Michael A. , Wang Larry , Seeger Robert C. , Kim Eugene S.
Published: April 2023

Supplemental Figure 1
Supplementary Table 3-8 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Table 3-8
Supplementary Data from YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer
Authors: Li Fan , Xu Yan , Liu Bovey , Singh Pankaj Kumar , Zhao Wei , Jin Jiankang , Han Guangchun , Scott Ailing W. , Dong Xiaochuan , Huo Longfei , Ma Lang , Pizzi Melissa Pool , Wang Ying , Li Yuan , Harada Kazuto , Xie Min , Skinner Heath D. , Ding Sheng , Wang Linghua , Krishnan Sunil , Johnson Randy L. , Song Shumei , Ajani Jaffer A.
Published: April 2023

Supplemental Figure 3. Combination inhibition of YAP1 and CDK6 eradicate CSCs population in radiation resistant cells A&B.
Supplementary Methods, Legends from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Methods, Legends
Supplementary Figure 1 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Authors: Yan Dongqing , Pomicter Anthony D. , Tantravahi Srinivas , Mason Clinton C. , Senina Anna V. , Ahmann Jonathan M. , Wang Qiang , Than Hein , Patel Ami B. , Heaton William L. , Eiring Anna M. , Clair Phillip M. , Gantz Kevin C. , Redwine Hannah M. , Swierczek Sabina I. , Halverson Brayden J. , Baloglu Erkan , Shacham Sharon , Khorashad Jamshid S. , Kelley Todd W. , Salama Mohamed E. , Miles Rodney R. , Boucher Kenneth M. , Prchal Josef T. , O'Hare Thomas , Deininger Michael W.
Published: April 2023

Supplementary Figure 1
Supplementary Figure 3 from Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
Authors: Karches Clara H. , Benmebarek Mohamed-Reda , Schmidbauer Moritz L. , Kurzay Mathias , Klaus Richard , Geiger Martina , Rataj Felicitas , Cadilha Bruno L. , Lesch Stefanie , Heise Constanze , Murr Ramona , vom Berg Johannes , Jastroch Martin , Lamp Daniel , Ding Jian , Duewell Peter , Niederfellner Gerhard , Sustmann Claudio , Endres Stefan , Klein Christian , Kobold Sebastian
Published: April 2023

Supplementary Figure 3: In contrast to SAR T cells, CAR T cells rely on the release of perforin for efficient killing.
Supplementary Figure 2 from Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
Authors: Karches Clara H. , Benmebarek Mohamed-Reda , Schmidbauer Moritz L. , Kurzay Mathias , Klaus Richard , Geiger Martina , Rataj Felicitas , Cadilha Bruno L. , Lesch Stefanie , Heise Constanze , Murr Ramona , vom Berg Johannes , Jastroch Martin , Lamp Daniel , Ding Jian , Duewell Peter , Niederfellner Gerhard , Sustmann Claudio , Endres Stefan , Klein Christian , Kobold Sebastian
Published: April 2023

Supplementary Figure 2: Soluble and bound EGFR ligands do not trigger unwanted SAR T cell activation, while antibodies monovalent and bivalent for SAR can trigger T cell activation to the same extent.
Supplementary Figure 1 from Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
Authors: Karches Clara H. , Benmebarek Mohamed-Reda , Schmidbauer Moritz L. , Kurzay Mathias , Klaus Richard , Geiger Martina , Rataj Felicitas , Cadilha Bruno L. , Lesch Stefanie , Heise Constanze , Murr Ramona , vom Berg Johannes , Jastroch Martin , Lamp Daniel , Ding Jian , Duewell Peter , Niederfellner Gerhard , Sustmann Claudio , Endres Stefan , Klein Christian , Kobold Sebastian
Published: April 2023

Supplementary Figure 1: Murine SAR expression and immunophenotyping of transduced T cells
Supplementary Video S4 from MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer
Authors: Wang Shiyan , Huang Junzhe , Li Chuangen , Zhao Liuyang , Wong Chi Chun , Zhai Jianning , Zhou Yunfei , Deng Wen , Zeng Yong , Gao Shanshan , Zhang Yanquan , Wang Guoping , Guan Xin Yuan , Wei Hong , Wong Sunny H. , He Housheng H. , Shay Jerry W. , Yu Jun
Published: April 2023

Supplementary Video S4
Supplementary Video S3 from MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer
Authors: Wang Shiyan , Huang Junzhe , Li Chuangen , Zhao Liuyang , Wong Chi Chun , Zhai Jianning , Zhou Yunfei , Deng Wen , Zeng Yong , Gao Shanshan , Zhang Yanquan , Wang Guoping , Guan Xin Yuan , Wei Hong , Wong Sunny H. , He Housheng H. , Shay Jerry W. , Yu Jun
Published: April 2023

Supplementary Video S3
Supplementary Video S2 from MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer
Authors: Wang Shiyan , Huang Junzhe , Li Chuangen , Zhao Liuyang , Wong Chi Chun , Zhai Jianning , Zhou Yunfei , Deng Wen , Zeng Yong , Gao Shanshan , Zhang Yanquan , Wang Guoping , Guan Xin Yuan , Wei Hong , Wong Sunny H. , He Housheng H. , Shay Jerry W. , Yu Jun
Published: April 2023

Supplementary Video S2
Supplementary Table S6 from MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer
Authors: Wang Shiyan , Huang Junzhe , Li Chuangen , Zhao Liuyang , Wong Chi Chun , Zhai Jianning , Zhou Yunfei , Deng Wen , Zeng Yong , Gao Shanshan , Zhang Yanquan , Wang Guoping , Guan Xin Yuan , Wei Hong , Wong Sunny H. , He Housheng H. , Shay Jerry W. , Yu Jun
Published: April 2023

Supplementary Table S6
Supplementary Data from MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer
Authors: Wang Shiyan , Huang Junzhe , Li Chuangen , Zhao Liuyang , Wong Chi Chun , Zhai Jianning , Zhou Yunfei , Deng Wen , Zeng Yong , Gao Shanshan , Zhang Yanquan , Wang Guoping , Guan Xin Yuan , Wei Hong , Wong Sunny H. , He Housheng H. , Shay Jerry W. , Yu Jun
Published: April 2023

Supplementary Materials and Methods, Figures, Tables
Table S1 from Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Authors: Toledo Rodrigo A. , Garralda Elena , Mitsi Maria , Pons Tirso , Monsech Jorge , Vega Estela , Otero Álvaro , Albarran Maria I. , Baños Natalia , Durán Yolanda , Bonilla Victoria , Sarno Francesca , Camacho-Artacho Marta , Sanchez-Perez Tania , Perea Sofia , Álvarez Rafael , De Martino Alba , Lietha Daniel , Blanco-Aparicio Carmen , Cubillo Antonio , Domínguez Orlando , Martínez-Torrecuadrada Jorge L. , Hidalgo Manuel
Published: April 2023

Table S1: Mutation analysis concordance between plasma cfDNA exome sequencing and tumor exome sequencing.
Tables S9-S10 from Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Authors: Amin-Mansour Ali , George Suzanne , Sioletic Stefano , Carter Scott L. , Rosenberg Mara , Taylor-Weiner Amaro , Stewart Chip , Chevalier Aaron , Seepo Sara , Tracy Adam , Getz Gad , Hornick Jason L. , Nucci Marisa R. , Quade Bradley , Demetri George D. , Raut Chandrajit P. , Garraway Levi A. , Van Allen Eliezer M. , Wagner Andrew J.
Published: April 2023

Supplementary Tables 9 and 10
Supplementary Figure 4 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer
Authors: Kandimalla Raju , Gao Feng , Matsuyama Takatoshi , Ishikawa Toshiaki , Uetake Hiroyuki , Takahashi Naoki , Yamada Yasuhide , Becerra Carlos , Kopetz Scott , Wang Xin , Goel Ajay
Published: April 2023

Supplementary Figure 4: MRC significantly predicted benefit of adjuvant chemotherapy in microsatellite stable stage III colorectal cancers KM plots depicted in panel A, B, C and D belong to MRC high risk category, while the KM plots in panel E, F, G and H belong to MRC low risk category. KM plots in panel A and E represents the analysis performed on combined stage II and III CRC patients, while panel B and F represents stage II analysis and panel C and G represents stage III patient's analysis separately. KM plots depicted in panel D and H represents the analysis performed on microsatellite stable stage III CRC patients.
Table S6 from Characterization of Alternative Splicing Events in HPV-Negative Head and Neck Squamous Cell Carcinoma Identifies an Oncogenic DOCK5 Variant
Authors: Liu Chao , Guo Theresa , Xu Guorong , Sakai Akihiro , Ren Shuling , Fukusumi Takahito , Ando Mizuo , Sadat Sayed , Saito Yuki , Khan Zubair , Fisch Kathleen M. , Califano Joseph
Published: April 2023

Correlations between the expression of DOCK5 variant and clinicopathological parameters in TCGA HPV negative HNSCC data
Supplementary Table S9 from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

Raw data of Fig. 4B.
Supplementary Table S5 from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

Raw data of Supplementary Fig. S6.
Supplementary Table S4 from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

Raw data of Fig. 2A.
Supplementary Data from Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Authors: Cowman Sophie J. , Fuja Daniel G. , Liu Xian-De , Tidwell Rebecca S. Slack , Kandula Neelima , Sirohi Deepika , Agarwal Archana M. , Emerson Lyska L. , Tripp Sheryl R. , Mohlman Jeffrey S. , Stonhill Miekan , Garcia Guillermina , Conley Christopher J. , Olalde Adam A. , Sargis Timothy , Ramirez-Torres Adela , Karam Jose A. , Wood Christopher G. , Sircar Kanishka , Tamboli Pheroze , Boucher Kenneth , Maughan Benjamin , Spike Benjamin T. , Ho Thai H. , Agarwal Neeraj , Jonasch Eric , Koh Mei Yee
Published: April 2023

Supplemental Figures
Supplementary Data from Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Authors: Cowman Sophie J. , Fuja Daniel G. , Liu Xian-De , Tidwell Rebecca S. Slack , Kandula Neelima , Sirohi Deepika , Agarwal Archana M. , Emerson Lyska L. , Tripp Sheryl R. , Mohlman Jeffrey S. , Stonhill Miekan , Garcia Guillermina , Conley Christopher J. , Olalde Adam A. , Sargis Timothy , Ramirez-Torres Adela , Karam Jose A. , Wood Christopher G. , Sircar Kanishka , Tamboli Pheroze , Boucher Kenneth , Maughan Benjamin , Spike Benjamin T. , Ho Thai H. , Agarwal Neeraj , Jonasch Eric , Koh Mei Yee
Published: April 2023

Supplemental Figure Legends
Supplementary Table S1 from High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Authors: Nagano Masaaki , Kohsaka Shinji , Ueno Toshihide , Kojima Shinya , Saka Kanju , Iwase Hirotaro , Kawazu Masahito , Mano Hiroyuki
Published: April 2023

Fifty-five recurrent ERRB2 mutations in the COSMIC database for the MANO method.
Supplementary Figure S4 from Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Authors: Higgs Brandon W. , Morehouse Christopher A. , Streicher Katie , Brohawn Philip Z. , Pilataxi Fernanda , Gupta Ashok , Ranade Koustubh
Published: April 2023

Supplemental Figure S4. Association of IFNγ mRNA signature status and survival in patients with TCGA UC (BLCA), NSCLC adenocarcinoma (LUAD), and squamous NSCLC (LUSC).
Supplementary Figure S3 from Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Authors: Higgs Brandon W. , Morehouse Christopher A. , Streicher Katie , Brohawn Philip Z. , Pilataxi Fernanda , Gupta Ashok , Ranade Koustubh
Published: April 2023

Supplemental Figure S3. Association of IFNγ+ signature with OS and PFS at higher cutoffs in NSCLC (A) and UC (B) patients.
Supplementary Figure S1 from Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Authors: Higgs Brandon W. , Morehouse Christopher A. , Streicher Katie , Brohawn Philip Z. , Pilataxi Fernanda , Gupta Ashok , Ranade Koustubh
Published: April 2023

Supplemental Figure S1. Study design
Supplementary Figure 8 from Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade
Authors: Rennier Keith , Shin Woo Jae , Krug Ethan , Virdi Gurpal , Pachynski Russell K.
Published: April 2023

Supplementary Figure 8. Knockdown of PTEN and PD-L1 Expression in DU145 Cells. A. Western blot analysis for PTEN expression after transfection with siRNA. Loading control bands are probed with anti-GAPDH antibody on the same blot. DU145 cells were transfected with either control siRNA or siRNA against PTEN. Relative band intensity was quantified and analyzed based on results from three independent experiments and presented as a ratio to the baseline PTEN expression in mock transfected cells (no siRNA) (n = 3). B. Western blot analysis for PTEN expression. Transfection of PTEN siRNA, but not Control siRNA, resulted in a significant decrease in PTEN expression. **p < 0.01 compared to Mock - No siRNA cells. C. Western blot analysis for PD-L1 expression after transfection with siRNA. Loading control bands are probed with anti-GAPDH antibody on the same blot. DU145 cells were transfected with either no siRNA (Mock), control siRNA or siRNA against PD-L1. Relative band intensity was quantified and analyzed based on results from three independent experiments and presented as a ratio to the baseline PD-L1 expression in mock transfected cells (n = 3). D. Quantified results for PD-L1 siRNA transfection Western blot (n = 3). Transfection of PD-L1 siRNA at the siRNA:transfection reagent ratio of both 4:10 and 5:10, resulted in a significant knockdown in PD-L1 expression, **p < 0.05 compared to Mock - No siRNA cells. E. Western blot analysis for PD-L1 expression after transfection with siRNA. Loading control bands are probed with anti-GAPDH antibody on the same blot. U2OS cells were transfected with either no siRNA (Mock), control siRNA or siRNA against PD-L1. Relative band intensity was quantified and analyzed based on results from three independent replicates and presented as a ratio to the baseline PD-L1 expression in mock transfected cells (n = 3). F. Quantified results for PD-L1 siRNA transfection Western blot (n = 3). Transfection of PD-L1 siRNA at the siRNA:transfection reagent ratio of 4:10 resulted in a significant knockdown of PD-L1 expression. **p < 0.05 compared to Mock - No siRNA cells. (n = 3).
Supplementary Legends from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Authors: Nava Rodrigues Daniel , Casiraghi Nicola , Romanel Alessandro , Crespo Mateus , Miranda Susana , Rescigno Pasquale , Figueiredo Ines , Riisnaes Ruth , Carreira Suzanne , Sumanasuriya Semini , Gasperini Paola , Sharp Adam , Mateo Joaquin , Makay Alan , McNair Christopher , Schiewer Matthew , Knudsen Karen , Boysen Gunther , Demichelis Francesca , de Bono Johann S.
Published: April 2023

Legends of supplementary figure and table.
Figure S5 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Authors: Nava Rodrigues Daniel , Casiraghi Nicola , Romanel Alessandro , Crespo Mateus , Miranda Susana , Rescigno Pasquale , Figueiredo Ines , Riisnaes Ruth , Carreira Suzanne , Sumanasuriya Semini , Gasperini Paola , Sharp Adam , Mateo Joaquin , Makay Alan , McNair Christopher , Schiewer Matthew , Knudsen Karen , Boysen Gunther , Demichelis Francesca , de Bono Johann S.
Published: April 2023

Figure S5
Figure S4 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Authors: Nava Rodrigues Daniel , Casiraghi Nicola , Romanel Alessandro , Crespo Mateus , Miranda Susana , Rescigno Pasquale , Figueiredo Ines , Riisnaes Ruth , Carreira Suzanne , Sumanasuriya Semini , Gasperini Paola , Sharp Adam , Mateo Joaquin , Makay Alan , McNair Christopher , Schiewer Matthew , Knudsen Karen , Boysen Gunther , Demichelis Francesca , de Bono Johann S.
Published: April 2023

Figure S4
Figure S3 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Authors: Nava Rodrigues Daniel , Casiraghi Nicola , Romanel Alessandro , Crespo Mateus , Miranda Susana , Rescigno Pasquale , Figueiredo Ines , Riisnaes Ruth , Carreira Suzanne , Sumanasuriya Semini , Gasperini Paola , Sharp Adam , Mateo Joaquin , Makay Alan , McNair Christopher , Schiewer Matthew , Knudsen Karen , Boysen Gunther , Demichelis Francesca , de Bono Johann S.
Published: April 2023

Figure S3
Supplementary Figure 4 from Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade
Authors: Rennier Keith , Shin Woo Jae , Krug Ethan , Virdi Gurpal , Pachynski Russell K.
Published: April 2023

Supplementary Figure 4. CMKLR1 knockdown negates chemerin's ability to decrease DU145 cell invasion. A-C. (Top). Representative 4X images showing tumor cell invasion of PBS or Recombinant Chemerin treated A. DU145, B. U2OS, and C. SKES cells transfected with Mock (no siRNA), Control siRNA, or CMKLR1 siRNA. Each sample set and condition were performed in triplicate wells. Overall migration was normalized to baseline cell migration using No matrigel matrix and No FBS gradient (n = 3). Each of the following groups were compared: No matrigel - No FBS, No matrigel - CM + 10% FBS, 1mg/mL matrigel + cells treated with 48h PBS, or 1mg/mL matrigel + cells treated with 48h 6nM recombinant human chemerin (rHchemerin). Scale bar = 100ÃŽÂ¼m. (Bottom). Quantified tumor cell invasion results for each subset of transfected A. DU145, B. U2OS, and C. SKES cells. Each set was treated with either PBS (vehicle) or 6nM Chemerin for 48h. Cells were processed as previously described, ran in duplicate wells and the relative sample absorbance was read at 590nm. Each respective sample absorbance is normalized to baseline migration using the no matrigel and no FBS control (*p < 0.05, n = 4 individual, repeated sample sets. NS = No significant difference).
Figure S1 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Authors: Nava Rodrigues Daniel , Casiraghi Nicola , Romanel Alessandro , Crespo Mateus , Miranda Susana , Rescigno Pasquale , Figueiredo Ines , Riisnaes Ruth , Carreira Suzanne , Sumanasuriya Semini , Gasperini Paola , Sharp Adam , Mateo Joaquin , Makay Alan , McNair Christopher , Schiewer Matthew , Knudsen Karen , Boysen Gunther , Demichelis Francesca , de Bono Johann S.
Published: April 2023

Figure S1
Supplementary Figure 2 from Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade
Authors: Rennier Keith , Shin Woo Jae , Krug Ethan , Virdi Gurpal , Pachynski Russell K.
Published: April 2023

Supplementary Figure 2. Assessing the effect of chemerin incubation on tumor cell proliferation. Each cell line was treated with PBS or 6nM chemerin concentration for 72h. Each day, triplicate wells were incubated with Alamar blue, and the absorbance was read, correlating to total number of cells per well (n = 3). Results show that chemerin does not affect overall cell proliferation over a 72h chemerin incubation compared to the paired PBS treated cells for each cell line. A. DU145, B. PC3, C. SKES, D. U2OS. E. In vitro proliferation of either vector control or RARRES2-transfected ("chemerin-expressing") DU145 tumor cells. F. Measurement by ELISA of secreted chemerin in conditioned media from control or chemerin-expressing DU145 cells. G. chemotaxis of purified human NK cells using transwell assays; RPMI (negative) and recombinant chemerin (positive) were used as control along with conditioned media from control and chemerin-expressing DU145 tumor lines. Representative of n=2 experiments, *p < 0.05.
Supplementary Figure 1 from Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade
Authors: Rennier Keith , Shin Woo Jae , Krug Ethan , Virdi Gurpal , Pachynski Russell K.
Published: April 2023

Supplementary Figure 1. Baseline CMKLR1 Expression in cell lines. A. PC3, B. DU145 CMKLR1 expression measured via FACS. C. Representative Western blot for baseline CMKLR1 expression for PC3 and DU145 cells, normalized to GAPDH loading control. D. SKES, E. U2OS cells CMKLR1 expression measured via FACS. F. Representative Western blot for baseline CMKLR1 expression, normalized to Actin loading control. Knockdown of CMKLR1 Expression in Human Cells. G. Representative Western blot and analysis for CMKLR1 expression after transfection with siRNA, using either 3:9 or 4:10 siRNA to transfection reagent ratio. Loading control bands were probed with anti-GAPDH antibody on the same blot. DU145 (A1, A2). H. CMKLR1 receptor expression via FACS in control vs CMKLR1 siRNA (4:10) transfected DU145 cells I-J. Western blot analysis for CMKLR1 expression using a 4:10 ratio of siRNA:transfection reagent. SKES (I1, I2), and U2OS (J1, J2) cells were transfected with either control siRNA or siRNA against CMKLR1. Relative band intensity was analyzed based on results from three independent experiments and presented as a ratio to the baseline CMKLR1 expression in non-transfected cells (n = 3). *p < 0.01 compared to non-transfected (NT) cells.
Supplementary Figure 3 from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer
Authors: Oza Amit M. , Estevez-Diz Maria , Grischke Eva-Maria , Hall Marcia , Marmé Frederik , Provencher Diane , Uyar Denise , Weberpals Johanne I. , Wenham Robert M. , Laing Naomi , Tracy Michael , Freshwater Tomoko , Lee Mark A. , Liu Ji , Qiu Jingjun , Rose Shelonitda , Rubin Eric H. , Moore Kathleen
Published: April 2023

Supplementary Figure 3
Supplementary Table S1 from AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells
Authors: Hampsch Riley A. , Wells Jason D. , Traphagen Nicole A. , McCleery Charlotte F. , Fields Jennifer L. , Shee Kevin , Dillon Lloye M. , Pooler Darcy B. , Lewis Lionel D. , Demidenko Eugene , Huang Yina H. , Marotti Jonathan D. , Goen Abigail E. , Kinlaw William B. , Miller Todd W.
Published: April 2023

Table S1 shows normalized mRNA counts from NanoString analysis of MCF-7 xenografts.
Supplementary Figure 2 from A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer
Authors: Oza Amit M. , Estevez-Diz Maria , Grischke Eva-Maria , Hall Marcia , Marmé Frederik , Provencher Diane , Uyar Denise , Weberpals Johanne I. , Wenham Robert M. , Laing Naomi , Tracy Michael , Freshwater Tomoko , Lee Mark A. , Liu Ji , Qiu Jingjun , Rose Shelonitda , Rubin Eric H. , Moore Kathleen
Published: April 2023

Supplementary Figure 2
Supplementary Figures from AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells
Authors: Hampsch Riley A. , Wells Jason D. , Traphagen Nicole A. , McCleery Charlotte F. , Fields Jennifer L. , Shee Kevin , Dillon Lloye M. , Pooler Darcy B. , Lewis Lionel D. , Demidenko Eugene , Huang Yina H. , Marotti Jonathan D. , Goen Abigail E. , Kinlaw William B. , Miller Todd W.
Published: April 2023

Fig. S1 shows that dormant ER+ breast cancer cells retain tumor-initiating capacity. Fig. S2 shows individual tumor growth curves. Fig. S3 shows IHC images for Ki67, cleaved caspase-3 and ER in xenografts. Fig. S4 shows Gene Set Variation Analysis of RNA-seq data from xenografts. Fig. S5 shows overlap of altered genes from RNA-seq data. Fig. S6 shows IHC images for AMPKï�¡2 and P-ACC in xenografts. Fig. S7 shows mTORC1 activation in MCF-7 tumors. Fig. S8 shows a transcriptional signature of FAO in human tumors. Fig. S9 shows mitochondrial content and activity in xenografts. Fig. S10 shows effects of AMPK knockdown on respiration. Fig. S11 shows that inhibition of FAO hastens tumor regression. Fig. S12 shows pharmacologic analysis of metformin. Fig. S13 shows metformin effects in MDA-MB-415 tumors. Fig. S14 shows that metformin prevents tumor regression. Fig. S15 shows that metformin does not alter fasting levels of blood glucose, serum insulin, or serum free fatty acids in mice. Fig. S16 show IHC images of P-ACC in tumors from mice treated with metformin. Fig. S17 shows AMPK effects on HCC-1500 cells and tumors. Fig. S18 shows the effects of high-fat diet on tumor regression. Fig. S19 shows IHC images of Ki67, CPT1Î±, and P-ACC in xenografts from mice treated with high-fat or low-fat diet.
Supplementary Data from Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing
Authors: Hensley Martee L. , Chavan Shweta S. , Solit David B. , Murali Rajmohan , Soslow Robert , Chiang Sarah , Jungbluth Achim A. , Bandlamudi Chaitanya , Srinivasan Preethi , Tap William D. , Rosenbaum Evan , Taylor Barry S. , Donoghue Mark T.A. , Hyman David M.
Published: April 2023

Supplementary Table 1
Supplementary Data from The Impact of Early-Phase Trial Design in the Drug Development Process
Authors: Conaway Mark R. , Petroni Gina R.
Published: April 2023

Supplemental Table S1. Parameters for generating toxicity, response and median survival profiles for a population of agents Supplementary Figure S1. 100 randomly selected drug profiles, A: toxicity; B: response rate; C: median survival for the population that matches agents entering the pipeline from 1993-2004 (section 2.6) Supplementary Figure S2. Plot of 100 randomly selected toxicity, reponse and median survival profiles for 4, 6 or 8 doses levels to be tested in the phase I trial (section 2.6) Supplemental Table S2. Proportion of drugs with two successful phase III trials among 17225 drugs with a phase I trial that has at least one safe dose, defined as a toxicity probability less than or equal to 20% (section 3.2) Supplemental Table S3.. Proportion of drugs with two successful phase III trials among 20000 drugs in the 'low toxicity' population (section 3.3) Supplemental Table S4. Proportion of drugs with two successful phase III trials using an initial phase I target of 30% (section 3.2) Supplementary Figure S4. Plot of proportion of agents with two successful phase II trials using a target of 30% for CRM and BOIN (section 3.2)
Supplementary Table S6 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

Pooled mouse PK model parameters for AZD3229
Supplementary Information from Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma
Authors: Mohme Malte , Maire Cecile L. , Geumann Ulf , Schliffke Simon , Dührsen Lasse , Fita Krystian , Akyüz Nuray , Binder Mascha , Westphal Manfred , Guenther Christine , Lamszus Katrin , Hermann Felix G. , Schmidt Nils Ole
Published: April 2023

Supplementary Legends and Methods
Figure S5 from Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma
Authors: Mohme Malte , Maire Cecile L. , Geumann Ulf , Schliffke Simon , Dührsen Lasse , Fita Krystian , Akyüz Nuray , Binder Mascha , Westphal Manfred , Guenther Christine , Lamszus Katrin , Hermann Felix G. , Schmidt Nils Ole
Published: April 2023

Suppl. Fig. 5. Spleen weight
Supplementary Table S2 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

Pharmacokinetic parameters for standard of care compounds in human and in mouse
Supplementary Table S1 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

Summary of plasma protein binding (% unbound) of AZD3229
Supplementary Figure S4 from The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Authors: Pilla Reddy Venkatesh , Anjum Rana , Grondine Michael , Smith Aaron , Bhavsar Deepa , Barry Evan , Guichard Sylvie M. , Shao Wenlin , Kettle Jason G. , Brown Crystal , Banks Erica , Jones Rhys D.O.
Published: April 2023

PKPD efficacy data of KIT probe compound (AZ12607208)
Supplementary Information from A Chimeric Signal Peptide–Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell–Specific Apoptosis
Authors: Lee Sok-Hyong , Khwaja Rehman Fatima , Tyler Kari C. , Yu Bing , Zhang Zhaobin , Osuka Satoru , Zerrouqi Abdessamad , Kaluzova Milota , Hadjipanayis Costas G. , Cummings Richard D. , Olson Jeffrey J. , Devi Narra S. , Van Meir Erwin G.
Published: April 2023

Table of contents: 1. Abbreviations 2. Author Contributions 3. Extended Material and Methods 4. Supplementary Figure Legends 5. Supplementary References
Figures S1-S7 from A Chimeric Signal Peptide–Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell–Specific Apoptosis
Authors: Lee Sok-Hyong , Khwaja Rehman Fatima , Tyler Kari C. , Yu Bing , Zhang Zhaobin , Osuka Satoru , Zerrouqi Abdessamad , Kaluzova Milota , Hadjipanayis Costas G. , Cummings Richard D. , Olson Jeffrey J. , Devi Narra S. , Van Meir Erwin G.
Published: April 2023

S1-S7
Supplementary Data from Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Authors: Gangat Naseema , Marinaccio Christian , Swords Ronan , Watts Justin M. , Gurbuxani Sandeep , Rademaker Alfred , Fought Angela J. , Frankfurt Olga , Altman Jessica K. , Wen Qiang Jeremy , Farnoud Noushin , Famulare Christopher A. , Patel Akshar , Tapia Roberto , Vallapureddy Rangit R. , Barath Stephanie , Graf Amy , Handlogten Amy , Zblewski Darci , Patnaik Mrinal M. , Al-kali Aref , Dinh Yvonne Trang , Englund Prahl Kristen , Patel Shradha , Nobrega Juan Carlos , Tejera Dalissa , Thomassen Amber , Gao Juehua , Ji Peng , Rampal Raajit K. , Giles Francis J. , Tefferi Ayalew , Stein Brady , Crispino John D.
Published: April 2023

Figure S1: Alisertib treatment did not result in a consistent cytokine response. Figure S2: Alisertib did not have a consistent effect on TGF-b levels. Figure S3: Alisertib induced GATA1 expression in the SET2 megakaryocytic cell line. Figure S4: AURKA inhibition induces megakaryocytic gene expression. Figure S5: Alisertib increases GATA1 expression in the bone marrow of patients on therapy. Table S1: Correlation of Genotype and prior JAK inhibitor therapy with response and adverse events Table S2: Summary of Treatment Related Adverse Events Table S3: Association between GATA1 staining, degree of fibrosis and clinical response
Figure S7 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Authors: Faramand Rawan , Jain Michael , Staedtke Verena , Kotani Hiroshi , Bai Renyuan , Reid Kayla , Lee Sae Bom , Spitler Kristen , Wang Xuefeng , Cao Biwei , Pinilla Javier , Lazaryan Aleksander , Khimani Farhad , Shah Bijal , Chavez Julio C. , Nishihori Taiga , Mishra Asmita , Mullinax John , Gonzalez Ricardo , Hussaini Mohammad , Dam Marian , Brandjes Brigett D. , Bachmeier Christina A. , Anasetti Claudio , Locke Frederick L. , Davila Marco L.
Published: April 2023

Early intervention in a patient with elevated baseline IL6
Table S2 from Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Authors: Liu Chao , Sadat Sayed H. , Ebisumoto Koji , Sakai Akihiro , Panuganti Bharat A. , Ren Shuling , Goto Yusuke , Haft Sunny , Fukusumi Takahito , Ando Mizuo , Saito Yuki , Guo Theresa , Tamayo Pablo , Yeerna Huwate , Kim William , Hubbard Jacqueline , Sharabi Andrew B. , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Correlations between cannabinoids exposure and clinicopathological parameters.
Table S1 from Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Authors: Liu Chao , Sadat Sayed H. , Ebisumoto Koji , Sakai Akihiro , Panuganti Bharat A. , Ren Shuling , Goto Yusuke , Haft Sunny , Fukusumi Takahito , Ando Mizuo , Saito Yuki , Guo Theresa , Tamayo Pablo , Yeerna Huwate , Kim William , Hubbard Jacqueline , Sharabi Andrew B. , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Expression of cannabinoids and their metabolites in plasma samples of HPV positive HNSCC patients identified by LC-MS/MS.
Supplementary Tables and Figures from Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia Patients
Authors: Taylor Olga A. , Brown Austin L. , Brackett Julienne , Dreyer ZoAnn E. , Moore Ida Ki , Mitby Pauline , Hooke Mary C. , Hockenberry Marilyn J. , Lupo Philip J. , Scheurer Michael E.
Published: April 2023

Supplementary Tables and Figures
Figure S1 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
Authors: Faramand Rawan , Jain Michael , Staedtke Verena , Kotani Hiroshi , Bai Renyuan , Reid Kayla , Lee Sae Bom , Spitler Kristen , Wang Xuefeng , Cao Biwei , Pinilla Javier , Lazaryan Aleksander , Khimani Farhad , Shah Bijal , Chavez Julio C. , Nishihori Taiga , Mishra Asmita , Mullinax John , Gonzalez Ricardo , Hussaini Mohammad , Dam Marian , Brandjes Brigett D. , Bachmeier Christina A. , Anasetti Claudio , Locke Frederick L. , Davila Marco L.
Published: April 2023

Institutional management guidelines for CRS adapted from the CARTOX working group criteria.
Supplementary Figure 2S - Lineweaver-Burk diagram for the substrate RH123 (A) and CFDA (B) in the absence (vehicle, DMSO) or presence of nilotinib (1-10 μM). from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
Authors: Alemany Regina , Moura David S. , Redondo Andres , Martinez-Trufero Javier , Calabuig Silvia , Saus Carlos , Obrador-Hevia Antonia , Ramos Rafael , Villar Victor H. , Valverde Claudia , Vaz Maria Angeles , Medina Javier , Felipe-Abrio Irene , Hindi Nadia , Taron Miguel , Martin-Broto Javier
Published: April 2023

C) Values of the kinetic parameters (Vmax and Km) in the absence (vehicle, DMSO) or presence of different concentrations of nilotinib. The constants were estimated with the Michaelis-Menten equation using the GraphPad Prism program. Each value represents the mean {plus minus} SD of three independent experiments. 1The maximal rate, Vmax reveals the number of substrate molecules being catalyzed per second. 2Km is that concentration of substrate at which half the active sites of the enzyme are filled.
Table S3 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Authors: Zhang Jiajun , Liu Weihai , Zou Changye , Zhao Zhiqiang , Lai Yuanying , Shi Zhi , Xie Xianbiao , Huang Gang , Wang Yongqian , Zhang Xuelin , Fan Zepei , Su Qiao , Yin Junqiang , Shen Jingnan
Published: April 2023

Primers used in this study.
Supplementary Data Legend from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Authors: Zhang Jiajun , Liu Weihai , Zou Changye , Zhao Zhiqiang , Lai Yuanying , Shi Zhi , Xie Xianbiao , Huang Gang , Wang Yongqian , Zhang Xuelin , Fan Zepei , Su Qiao , Yin Junqiang , Shen Jingnan
Published: April 2023

Supplementary data legend
Figure S3 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Authors: Zhang Jiajun , Liu Weihai , Zou Changye , Zhao Zhiqiang , Lai Yuanying , Shi Zhi , Xie Xianbiao , Huang Gang , Wang Yongqian , Zhang Xuelin , Fan Zepei , Su Qiao , Yin Junqiang , Shen Jingnan
Published: April 2023

Enrichment analysis of THZ2-sensitive genes in osteosarcoma.
Figure S1 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Authors: Zhang Jiajun , Liu Weihai , Zou Changye , Zhao Zhiqiang , Lai Yuanying , Shi Zhi , Xie Xianbiao , Huang Gang , Wang Yongqian , Zhang Xuelin , Fan Zepei , Su Qiao , Yin Junqiang , Shen Jingnan
Published: April 2023

Enrichment analysis of super-enhancer-associated genes in osteosarcoma.
Supplementary Figure S1 from Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms
Authors: Peran Ivana , Madhavan Subha , Byers Stephen W. , McCoy Matthew D.
Published: April 2023

Comparison of cancer stage distribution at the time of diagnosis and survival plots between TCGA subsets and SEER registry.
Figure S1 to S5 from The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival
Authors: Santegoets Saskia J. , van Ham Vanessa J. , Ehsan Ilina , Charoentong Pornpimol , Duurland Chantal L. , van Unen Vincent , Höllt Thomas , van der Velden Lilly-Ann , van Egmond Sylvia L. , Kortekaas Kim E. , de Vos van Steenwijk Peggy J. , van Poelgeest Mariëtte I.E. , Welters Marij J.P. , van der Burg Sjoerd H.
Published: April 2023

Supplemental figures
Figure S1 from Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy
Authors: Narasimhan Vignesh , Wright Josephine A. , Churchill Michael , Wang Tongtong , Rosati Rachele , Lannagan Tamsin R.M. , Vrbanac Laura , Richardson Anne B. , Kobayashi Hiroki , Price Timothy , Tye Gayle X.Y. , Marker Julie , Hewett Peter J. , Flood Michael P. , Pereira Shalini , Whitney G. Adam , Michael Michael , Tie Jeanne , Mukherjee Siddhartha , Grandori Carla , Heriot Alexander G. , Worthley Daniel L. , Ramsay Robert G. , Woods Susan L.
Published: April 2023

Characterisation of CRPM tissue and peritonoids.
Table S1 from Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials
Authors: Terbuch Angelika , Tiu Crescens , Candilejo Irene Moreno , Scaranti Mariana , Curcean Andra , Bar Dan , Estevez Timon Miriam , Ameratunga Malaka , Ang Joo Ern , Ratoff Jonathan , Minchom Anna R. , Banerji Udai , de Bono Johann S. , Tunariu Nina , Lopez Juanita S.
Published: April 2023

Table S1. Frequency of DILD as per category
Supplementary Data from Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer
Authors: Mostaghel Elahe A. , Zhang Ailin , Hernandez Susana , Marck Brett T. , Zhang Xiaotun , Tamae Daniel , Biehl Heather E. , Tretiakova Maria , Bartlett Jon , Burns John , Dumpit Ruth , Ang Lisa , Matsumoto Alvin M. , Penning Trevor M. , Balk Steven P. , Morrissey Colm , Corey Eva , True Lawrence D. , Nelson Peter S.
Published: April 2023

Supplementary Methods and Supplementary Tables 1-3
Supplementary Data from A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2)
Authors: Freedland Stephen J. , Allen Jenifer , Jarman Aubrey , Oyekunle Taofik , Armstrong Andrew J. , Moul Judd W. , Sandler Howard M. , Posadas Edwin , Levin Dana , Wiggins Emily , Howard Lauren E. , Wu Yuan , Lin Pao-Hwa
Published: April 2023

Supplemental table 1: Between arm comparison of PSADT with and without hemoconcentration adjustment among patients who completed 3-month visit. Supplemental table 2: Frequency of self-reported adverse events/ side effects at baseline and 6 months by treatment arm
Supplementary Table S7 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Table S7
Supplementary Figure 4 from Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Authors: Marciscano Ariel E. , Ghasemzadeh Ali , Nirschl Thomas R. , Theodros Debebe , Kochel Christina M. , Francica Brian J. , Muroyama Yuki , Anders Robert A. , Sharabi Andrew B. , Velarde Esteban , Mao Wendy , Chaudhary Kunal R. , Chaimowitz Matthew G. , Wong John , Selby Mark J. , Thudium Kent B. , Korman Alan J. , Ulmert David , Thorek Daniel L.J. , DeWeese Theodore L. , Drake Charles G.
Published: April 2023

Quantitative analysis of radiation-induced changes in peripheral blood subsets over time.
Supplementary Table S5 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Table S5
Supplementary Table S3 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Table S3